Early diagnosis is crucial for the treatment and cure of a range of pathologies including cancers. The challenge diagnosis is to quantify the level of biomarkers at very low concentrations.
Chemotherapy revolutionised cancer treatment when it was first applied in the 1940s. Since then, these drugs have been refined into more selective targeted therapies.
Recent progress in material chemistry has enabled the scientists to combine therapeutic and diagnostic agents on a single nanoplatform to simultaneously treat and monitor disease.
In the regenerative medicine focus area of the ACN, researchers are developing new materials and methods to exert control over lineage determination in vitro and in vivo.
